



Patients With More Severe PsO Are More Likely  
to Have Obesity vs. Patients With Mild PsO<sup>1</sup>

Note: Included studies defining obesity as BMI  $\geq 30$  kg/m<sup>2</sup>.



A High BMI is Associated With<sup>2,3</sup>

Increased risk  
of developing PsO


Greater  
disease severity  
in PsO

Obesity and Psoriatic Disease Are Inflammatory  
States With Overlapping Comorbidities

Note: Additional comorbidities may exist beyond those listed here.

Bidirectional Relationship Between  
Chronic Inflammation in PsO and Obesity<sup>9-12</sup>Patients With Comorbid Obesity  
Are More Likely to Have<sup>13-16</sup>Delphi Expert Consensus on the  
Impact of Obesity on PsO Therapies<sup>14</sup>

Obesity **decreases the efficacy of both biologic and conventional oral PsO therapies**, and may also **increase the risk of side effects** with conventional oral therapies



**Weight control** is an important aspect of PsO management



Dermatology providers should be encouraged to take **ownership of weight management**



Explore the other infographics in the **Comorbidities in Psoriasis** series



\*Odds ratio; <sup>b</sup>Obesity defined as BMI  $\geq 30$  kg/m<sup>2</sup>; <sup>c</sup>Obesity definition ranged from BMI  $\geq 30$  kg/m<sup>2</sup> to  $<35$  kg/m<sup>2</sup>; <sup>d</sup>Definition of obesity varied between studies; <sup>e</sup>Obesity defined as BMI  $\geq 28$  kg/m<sup>2</sup>.

BMI=Body Mass Index; DC=Dendritic Cells; FFA=Free Fatty Acid; IFN=Interferon; IL=Interleukin; PsA=Psoriatic Arthritis; PsO=Psoriasis; QoL=Quality of Life; Th=T Helper; TNF=Tumor Necrosis Factor; WAT=White Adipose Tissue.

1. Armstrong AW, et al. *Nutr Diabetes*. 2012;2(12):e54. 2. Wang H, et al. *Sci Rep*. 2025;15(1):11158. 3. Budu-Aggrey A, et al. *PLoS Med*. 2019;16(1):e1002739. 4. Scala E, et al. *Life (Basel)*. 2024;14(6):733. 5. Gupta S, et al. *Rheumatol Int*. 2021;41(2):275-284. 6. Kloock S, et al. *Pharmacol Ther*. 2023;251:108549. 7. Daniel BS. *Aust J Gen Pract*. 2020;49(7):433-437. 8. Gerardo G, et al. *Curr Obes Rep*. 2025;14(1):5. 9. Guo Z, et al. *JID Innov*. 2022;2(1):100064. 10. Krüger K. *Dtsch Z Sportmed*. 2017;68:163-169. 11. Kamata M, Tada Y. *Front Immunol*. 2023;14:1286344.

12. Paroutoglou K, et al. *Curr Obes Rep*. 2020;9(3):165-178. 13. Pirro F, et al. *Clin Drug Investig*. 2021;41(10):917-925. 14. Burshtein J, et al. *J Am Acad Dermatol*. 2025;92(4):807-805. 15. Scher JU, et al. *Nat Rev Rheumatol*. 2019;15(3):153-166. 16. Rathod A, et al. *Indian Dermatol Online J*. 2022;13(5):606-610. 17. Herron MD, et al. *Arch Dermatol*. 2005;141(12):1527-1534. 18. Czarnecka A, et al. *Medicina (Kaunas)*. 2023;59(11):2006. 19. Chen Y, et al. *Ann Med*. 2023;55(1):2231847.